TruSight Myeloid Panel

TruSight Myeloid Panel

The TruSight Myeloid Sequencing Panel includes an expert-designed, Illumina tested oligo pool that generates 568 amplicons targeting full tumor suppressor genes or exonic hotspots in 54 genes associated with myeloid malignancies.

Catalog ID(s)
FC-130-1010 (96 samples)
FC-130-1003 (96 indices, 384 samples)
Order Now Support Training

TruSight Myeloid Gene List

ABL1 ASXL1
CBLC ATRX
CKDN2A BCOR
CEBPA BCORL1 BRAF CALR CBL CBLB CSF3R CUX1
GNAS DNMT3A
HRAS ETV6/TEL
IDH1 EZH2 FBXW7 FLT3 GATA1 GATA2 IDH2 IKZF1
MYD88 JAK2
NOTCH1 JAK3
NPM1 KDM6A KRAS KIT MLL MPL NRAS PDGFRA
SMC1A PHF6
SMC3 PTEN
SRSF2 PTPN11 RAS21 RUNX1 SETBP1 SF3B1 STAG2 TET2 TP53 U2AF1 WT1 ZRSR2

Please rotate your device for details

* Library prep is compatible with all Illumina instruments. Recommended instruments chosen based on typical output and analysis need for selected application.
† Based on 95% amplicons at > 500x.
Project Recommendations
Species Compatibility Human
Recommended Illumina Instrument* MiniSeq MiSeq NextSeq 500
Recommended Samples per run† 2 to 3 8 8 (v3 chemistry) 40 96
Run Mode Mid Output High Output -- Mid Output High Output
Max Recommended Read Length Up to 2x150 bp Up to 2x150 bp Up to 2x150 bp Up to 2x150 bp Up to 2x150 bp
Recommended Secondary Analysis
  • Local Run Manager Amplicon
  • BaseSpaceTruSeq Amplicon
  • MiSeq Reporter TruSeq Amplicon Workflow
  • TruSeq Amplicon v1.1 BaseSpace App
Recommended Down Stream Analysis VariantStudio
Order Now Support Training
For Research Use Only

Not for use in diagnostic procedures (except as specifically noted).

Innovative technologies

At Illumina, our goal is to apply innovative technologies to the analysis of genetic variation and function, making studies possible that were not even imaginable just a few years ago. It is mission critical for us to deliver innovative, flexible, and scalable solutions to meet the needs of our customers. As a global company that places high value on collaborative interactions, rapid delivery of solutions, and providing the highest level of quality, we strive to meet this challenge. Illumina innovative sequencing and array technologies are fueling groundbreaking advancements in life science research, translational and consumer genomics, and molecular diagnostics.

All trademarks are the property of Illumina, Inc. or their respective owners.
For specific trademark information, see emea.illumina.com/company/legal.html.

© 2026 Illumina, Inc. All rights reserved.